Loading quotes...

Forecast

The analysts' average price target is €1,207.92 (+3.58%). The median is €1,230.43 (+5.51%).

Buy	33
Hold	9
Sell	3

News Go to news feed

Eli Lilly reaches new all-time high thanks to strong demand for tirzepatide products

Eli Lilly’s stock climbed to a new record, trading for the first time at $1,300 per share, driven by strong demand for the tirzepatide-based drugs Zepbound and Mounjaro. The two medicines generated about $15 billion in the second quarter; group revenues rose 48 percent overall to $23 billion. Investors are watching third-quarter figures expected on October 29, while Eli Lilly is simultaneously making acquisitions and expanding collaborations in AI and LNP areas, most recently with METiS TechBio. » More on deraktionaer.de
Eli Lilly receives EMA recommendation for weight-loss pill Foundayo

An EMA committee has recommended approval of Foundayo for weight control and for the treatment of type 2 diabetes in adults. The European Commission must still agree to the recommendation before Eli Lilly can market the drug in the EU. Foundayo would be, after Wegovy from Novo Nordisk, the second oral weight‑loss pill in the EU and increases competitive pressure on Novo, whose share price has fallen significantly from its peak. » More on manager-magazin.de
Eli Lilly ramps R&D and acquisitions to replace GLP-1 revenue before 2030s patent cliff

Eli Lilly, whose GLP-1 weight-loss and diabetes drugs generated 62% of trailing 12‑month revenue and helped push its market cap above $1 trillion, is spending heavily to diversify its pipeline before patents lapse in the 2030s. The company increased R&D to $13.3 billion in 2025 (and $7.3 billion in H1 2026) and has struck 31 deals this year, spending roughly $18 billion on acquisitions and licenses including Kelonia, Centessa and AtaiBeckley. Lilly is investing across oncology, neurology, sleep and psychedelics, and backing AI drug discovery with a $1 billion Nvidia partnership to seed next-generation blockbusters. CEO Dave Ricks says the moves aim to sustain growth rather than return capital if the GLP-1 franchise declines. » More on forbes.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Eli Lilly & Co has already paid €4.48 in dividends. The last payout was in September.

Financials

In the last quarter, Eli Lilly & Co had revenue of €20.13bn and net profit of €6.22bn

(EUR)	June 2026	YoY
Revenue	20.13bn	52.50%
Gross profit	17.27bn	55.24%
Net profit	6.22bn	29.44%
EBITDA	11.38bn	78.91%

Fundamentals

Metric	Value
Market capitalization	€1.07tn
Number of shares	941.36m
52-week high/low	€1,169.15 - €707.52
Dividend yield	0.51%
Dividends TTM	€5.76
Beta	0.45
P/E ratio	42.51
PEG ratio	0.45
P/B ratio	33.47
P/S ratio	15.02

Company profile

Eli Lilly and Company erforscht, entwickelt und vermarktet weltweit Humanarzneimittel. Es bietet Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, Insulin Lispro, Insulin Lispro Protamin, Insulin Lispro Mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R und Humulin U-500 für Diabetes; und Jardiance, Trajenta und Trulicity für Typ-2-Diabetes. Das Unternehmen bietet Alimta für nicht-kleinzelligen Lungenkrebs (NSCLC) und bösartiges Pleuramesotheliom; Cyramza für metastasierenden Magenkrebs, Adenokarzinom des gastroösophagealen Übergangs, metastasierenden NSCLC, metastasierenden kolorektalen Krebs und hepatozelluläres Karzinom; Erbitux für kolorektale Karzinome und verschiedene Kopf- und Halskrebsarten; Retevmo für metastasierten NSCLC, medullären Schilddrüsenkrebs und Schilddrüsenkrebs; Tyvyt für rezidivierte oder refraktäre klassische Hodgkin-Lymphome und nicht-squamösen NSCLC; und Verzenio für HR+, HER2- metastasierten Brustkrebs, knotenpositiven und frühen Brustkrebs. Es bietet Olumiant für rheumatoide Arthritis und Taltz für Plaque-Psoriasis, psoriatische Arthritis, ankylosierende Spondylitis und nicht-radiographische axiale Spondylarthritis. Das Unternehmen bietet Cymbalta für depressive Störungen, diabetische periphere neuropathische Schmerzen, generalisierte Angststörungen, Fibromyalgie und chronische Muskel-Skelett-Schmerzen; Emgality für Migräne-Prävention und episodische Cluster-Kopfschmerzen; und Zyprexa für Schizophrenie, bipolare Störung und bipolare Erhaltung. Seine Bamlanivimab und Etesevimab und Bebtelovimab für COVID-19; Cialis für erektile Dysfunktion und benigne Prostatahyperplasie; und Forteo für Osteoporose. Das Unternehmen arbeitet mit der Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., AbCellera Biologics Inc., Junshi Biosciences, Regor Therapeutics Group, Lycia Therapeutics, Inc., Kumquat Biosciences Inc., Entos Pharmaceuticals Inc. und Foghorn Therapeutics Inc. zusammen. Eli Lilly and Company wurde 1876 gegründet und hat seinen Hauptsitz in Indianapolis, Indiana.

Name	Eli Lilly & Co
CEO	David A. Ricks
Headquarters	Indianapolis, in USA
Website	lilly.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	01/06/1972
Employees	50,000